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Abstract
In the last decades, cellular senescence is viewed as a complex mechanism involved in different processes, ranging from
tumor suppression to induction of age-related degenerative alterations. Senescence-inducing stimuli are myriad and,
recently, we and others have demonstrated the role exerted by microRNAs in the induction and maintenance of senescence,
by the identification of a subset of Senescence-Associated microRNAs (SAmiRs) up-regulated during replicative or stress-
induced senescence and able to induce a premature senescent phenotype when over-expressed in human primary cells.
With the intent to find novel direct targets of two specific SAmiRs, SAmiR-494 and -486-5p, and cellular pathways which
they are involved in, we performed a comparative analysis of gene expression profiles available in literature to select genes
down-regulated upon replicative senescence of human primary fibroblasts. Among them, we searched for SAmiR’s
candidate targets by analyzing with different target prediction algorithms their 3’UTR for the presence of SAmiR-binding
sites. The expression profiles of selected candidates have been validated on replicative and stress-induced senescence and
the targeting of the 3’UTRs was assessed by luciferase assay. Results allowed us to identify Cell Division Cycle Associated 2
(CDCA2) and Inhibitor of DNA binding/differentiation type 4 (ID4) as novel targets of SAmiR-494 and SAmiR-486-5p,
respectively. Furthermore, we demonstrated that the over-expression of CDCA2 in human primary fibroblasts was able to
partially counteract etoposide-induced senescence by mitigating the activation of DNA Damage Response.
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Introduction
Described for the first time in 1961 by Hayflick and Moorhead
[1] as a process that limited the proliferation of normal human
cells in culture, cellular senescence currently refers to the
essentially irreversible growth arrest that occurs when proliferating
cells encounter a genotoxic stress and reveals a complex
phenomenon incorporating both genetic and environmental
components acting through convergent pathways. With the
possible exception of embryonic stem cells [2], most division-
competent cells, including adult stem cells and some tumor cells,
can undergo senescence [3].
Cellular senescence is thought to have evolved as a mechanism
to prevent that damaged DNA could be replicated and passed on
to future generations of cells, thus being considered a tumor
suppressor mechanism [3]. Nevertheless, despite their inability to
replicate, senescent cells are metabolically active and develop an
aberrant gene expression profile with proinflammatory behaviour,
the so-called Senescence Associated Secretory Phenotype (SASP),
that can induce or accelerate changes in normal surrounding
tissues, explaining the possible implication in tumor promotion,
aging and age-related pathologies [4]. Very recently, it has been
reported that cellular senescence contributes also to embryonic
development, both in mice and humans [5–6].
Distinctive features of senescent cells include enlarged and
flattened morphology, the appearance of senescence-associated
heterochromatin foci (SAHF), accumulation of senescence-associ-
ated DNA-damage foci (SDFs) and expression of Senescence-
Associated b-galactosidase (SA-b-gal) [4].
Many senescence-inducing stimuli cause epigenomic disruption
or genomic damage, like the gradual attrition of telomeres with
each S phase [7], that generates a persistent DNA damage
response (DDR), which initiates and maintains the senescence
growth arrest of human cells both in culture and in vivo [8–9].
Persistent DDR signaling generated at nontelomeric sites also
leads to the senescence growth arrest, such as that derived by
strong mitogenic signals delivered by certain oncogenes or highly
expressed pro-proliferative genes, that cause misfired replication
origins and replication fork collapse [10–12]. Treatments with
cytotoxic chemotherapeutic agents, such as etoposide, that cause
DNA double strand breaks, also induce premature senescence via
the p53 pathway [13]. Senescence can also occur, however,
without detectable DDR signaling. These stresses could include
inappropriate substrates or serum or oxidative stress, as the
Reactive Oxygen Species (ROS) production after treatment with
oxidative stress agents, such as the glutathione depletor Diethyl-
maleate (DEM) [14–15].
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In the last years microRNAs (miRs) have added a new layer of
complexity to the comprehension of molecular mechanisms
underlying senescence. Each miR can recognize up to hundred
different targets, thus influencing a large variety of cellular
processes [16]. We and others have recently demonstrated that
some miRs are involved in the process of cellular senescence [17–
20]. In particular, we have found a subset of five Senescence-
Associated miRs (SAmiRs) up-regulated during Human Diploid
Fibroblasts (HDFs) replicative senescence, whose ectopic expres-
sion in young cells promoted the premature senescence program
by inducing DNA damage and ROS accumulation.
The main aim of this study has been the identification of novel
mRNA targets of two selected SAmiRs, SAmiR-486-5p and
SAmiR-494. We chose SAmiR-486-5p, as we previously showed
that this miR was the most robust up-regulated upon replicative
senescence and significantly up-regulated upon Etoposide-Induced
Senescence (EIS) of HDFs and in human primary skin fibroblasts
from old donors [17]. Furthermore, Kim and colleagues demon-
strated that the over-expression of SAmiR-486-5p was able to
induce premature senescence also in human adipose tissue-derived
stem cells, by inhibiting SIRT1 [21]. We also chose SAmiR-494,
as its over-expression seemed to better recapitulate all the features
of a senescent phenotype, including reduced cell proliferation,
induction of SA-b-gal, SAHFs, DNA damage, SDFs and ROS
accumulation. Moreover, it resulted up-regulated also in DEM -
Induced Senescence (DIS) [17] and its over-expression was able to
induce senescence not only in HDFs, but also in cancer cells [22].
Our strategy has been to look for new SAmiR targets among the
mRNAs down-regulated in HDF senescent cells, comparing six
different gene expression profiles available in literature, selecting
genes whose expression was reduced in at least three different
arrays and searching for SAmiR’s responsive elements into their
3’UTR by the use of different target prediction algorithms.
This approach allowed us to identify Cell Division Cycle
Associated 2 (CDCA2) and Inhibitor of DNA binding/differen-
tiation type 4 (ID4) as novel targets of SAmiR-494 and SAmiR-
486-5p, respectively. Moreover, we have also demonstrated that
the transient over-expression of CDCA2 in HDFs is able to
partially counteract the premature senescent phenotype induced
by etoposide treatment.
Materials and Methods
Bioinformatics analysis
We took advantage of available data reporting gene expression
profiles in replicative senescent HDFs. Normalized data from 6
microarrays [23–28] have been crossed in order to select a list of
common genes down-regulated in senescence, with a fold
variation$1.5. We obtained a list of 139 genes down-regulated
upon HDFs replicative senescence (Table S1). Functional anno-
tations were obtained on PubMed.gov. For the identification of
putative targets of SAmiR-494 or SAmiR-486-5p, the genes in the
list have been analyzed with four different target prediction
algorithms (Target Scan v6.2, miRDB, Diana, miRanda) and
putative targets predicted by at least two algorithms have been
selected for further studies.
Real time PCR
Total RNA was extracted with TRIzol Reagent (Life Technol-
ogies) and quantified by Nanodrop (Thermo Scientific, Wilming-
ton, DE). The first-strand cDNA was synthesized according to the
manufacturer’s instructions (SS VILO Mastermix- Life Technol-
ogies). Real-time RT-PCR was carried out on an iCycler (BioRad)
using Express Greener QPCR Master mix (Life Technologies).
The housekeeping beta-actin (ACTB) mRNA was used as an
internal reference gene for normalization. PCR reactions were
performed on biological duplicates or triplicates and in experi-
mental triplicate. Fold changes were calculated using 22DDCt
method, by the formula: 22(sample DCt - calibrator DCt), comparing
results from experimental samples (Replicative senescent cells,
Etoposide-induced senescent cells or DEM-induced senescent
cells) with both a calibrator (young PDL 33 cells for RS; DMSO
treated cells for EIS and DIS) and the reference gene ACTB. DCt
is the difference between the amplification fluorescent thresholds
of the gene of interest and ACTB. The list of the primers used is
reported in Table S2.
TaqMan MiRNA Assay Kit (Applied Bio-systems, Foster City,
CA) was used to detect the expression of mature miRNAs. Briefly,
100 ng of total RNA was reversely transcribed (RT) at 16 uC for
30 min, 42 uC for 30 min and 85 uC for 5 min in 15 ml reaction
volume. Two ml of RT product were used for PCR reaction in a
final volume of 20 ml. The PCR reaction started with an initial
denaturation step at 90 uC for 10 min, followed by 40 cycles of 95
uC for 15 sec and 60 uC for 1 min. Small nucleolar RNA RNU6
(Applied Biosystems, Foster City, CA) was used for normalization.
PCR reactions were performed in triplicate and fold changes were
calculated using 22DDCt method, where DCt is the difference
between the amplification fluorescent thresholds of the miRNA of
interest and the RNA of RNU6.
Cell cultures, treatments and transfections
Normal human primary fibroblasts IMR90 and human
embryonic kidney HEK-293 cells were obtained from American
Type Culture Collection (Manassas, VA). Cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% (v/v) fetal bovine serum and 1% penicillin/streptomycin
(Gibco). Cultures were maintained at 37 uC in a 5% CO2-
humidified atmosphere.
The IMR90 population doubling level (PDL) was calculated by
using the formula: DPDL = log(nh/ni)/log2, where ni is the initial
number of cells and nh is the final number of cells at each passage.
The cells were used at 33 PDL (young) or 58 PDL (senescent)
(Fig.S1).
To induce premature senescence, IMR90 at PDL 33 were
treated with 150 mM DEM on alternate days for 10 days or with
20 mM etoposide (both from SIGMA-ALDRICH) for 24 h and
then subcultured for 10 days more (Fig.S1).
Transfection of IMR90 cells at PDL 33 with synthetic pre-miR
precursors (Ambion), miR inhibitors (Exiqon) or siRNAs (Dhar-
macon) were performed using Lipofectamine RNAiMAX Trans-
fection Reagent (Life Technologies) with the reverse protocol
following the manufacturer’s instructions. Pre-miRs, miR inhib-
itors and siRNAs were used at 100 nM.
Transfection of IMR90 cells at PDL 33 with CMV-CDCA2
and CMV-ID4, as well as co-transfection of HEK-293 with both
luciferase constructs and pre-miRs were performed using Lipo-
fectamine 2000 (Life Technologies) following the manufacturer’s
instructions.
Plasmid construction
With the exception of ID4, for which it has been cloned a
portion of 300 bp containing the putative SAmiR-486-5p binding
site, the whole 3’UTRs sequences of CDCA2, FOXM1, NUSAP1
and BUB1b have been cloned by PCR amplification on human
genomic DNA, using primer pairs with XhoI and SalI restriction
enzyme sites in the forward primers and XbaI in the reverse
primers. A 430 bp portion of the 3’UTR of human OLFM4,
containing the validated SAmiR-486-5p binding site [29], was
Novel SAmiR Direct Targets
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cloned as positive control using primer pairs with SalI restriction
enzyme sites in the forward primers and XbaI in the reverse
primers. All PCR products were cloned into the pMIR-GLO
vector (Promega) between the XhoI and the XbaI site,
downstream the Firefly luciferase (Normal clones). The inverted
3’UTR of CDCA2, ID4 and OLFM4 (Reverse clones) were
cloned by digestion of Forward clones with SalI, that allowed the
excision of the 3’UTR, and by recloning digested fragment in SalI
unique site. The orientation of the inserted fragments were
established by digestions and confirmed with sequencing. The
3’UTRs of CDCA2 and ID4 containing point mutations in the
SAmiR seed region (Mutated clones) were obtained by PCR using
the Quik Change II XL site direct mutagenesis kit (Agilent),
following the manufacturer’s instructions. Mutations were con-
firmed by sequencing.
The coding sequences of CDCA2 and ID4 were amplified by
PCR from ULTIMATEHORF CLONE ID IOH44066 and
ULTIMATEHORF CLONE ID IOH12413 (Life Technologies),
respectively, and cloned into the pEGFPN1 vector, in place of the
GFP coding sequence, between the AgeI and NotI sites. The
obtained vectors were named CMV-CDCA2 and CMV-ID4. All
primers used for plasmids construction and the oligos containing
the mutated SAmiR seed regions are reported in Table S3.
Luciferase Reporter Assay
For luciferase assays, human HEK-293 cells were plated at
86104 cells per well on 48 well plates (BD Falcon) 12 h before
transfection. The Normal, Reverse or Mutated luciferase con-
structs (100 ng) were co-transfected with 50 nM pre-miRs. All
transfection experiments were done in triplicate and each
experiment was repeated three times. The Renilla luciferase
reporter, contained into the pMIR-GLO vector, was used as an
internal control. The luciferase activity was measured 48 hours
after transfection using a Dual Luciferase Reporter Assay System
(Promega) according to manufacturer’s instructions, on a 20/20n
Luminometer instrument (Turner BioSystems). The data gener-
ated were expressed as relative to control-miR transfected cells,
after normalization to Renilla luciferase reading.
SA-b-gal assay and BrdU assay
SA-b-gal was assayed according to Dimri et al. [30]. Briefly, cells
were washed twice with PBS, fixed with 2% formaldehyde and
0.2% glutaraldehyde in PBS, and washed twice in PBS. Then, cells
were stained overnight in X-gal staining solution [1 mg/ml X-gal,
40 mM citric acid/sodium phosphate (pH 6.0), 5 mM potassium
ferricyanide, 5 mM potassium ferrocyanide, 150 mM NaCl,
2 mM MgCl2] at 37uC.
For BrdU (5-bromo-2-deoxyuridine) incorporation assay
(ROCHE), cells were seeded on glass coverslips and transfected
with siRNAs to induce the knock-down of SAmiR targets, or
transfected with CMV-CDCA2, CMV-ID4 or CMV-NEO (as
control plasmid) and treated with 20 mM etoposide to induce EIS
or with 150 mM DEM to induce DIS. 72 h after transfection
(siRNAs) or 24 h after treatments (48 h after plasmids over-
expression), cells were incubated for 4 h with BrdU (10 mM) and
fixed following the kit instructions. Coverslips were incubated with
a primary anti-BrdU and a secondary fluorescein-conjugated
antibodies and then counterstained with Hoechst 33258, rinsed
and mounted in Moviol on glass slides. The fluorescent signal was
visualized with an epifluorescent microscope Leica DM IL LED
FLUO (Leica Microsystems). At least 300 cells were counted in
triplicate experiments.
Immunofluorescence
To perform c-H2AX staining, IMR90 at PDL33 were plated on
glass coverslips, transfected with CMV-NEO control vector or
CMV-CDCA2 for 24 h and, then, treated with 20 mM etoposide.
Coverslips were collected at 0 h, 6 h and 18 h after treatment,
fixed with 4% paraformaldehyde in PBS for 30 minutes at RT,
permeabilized with 10% FBS, 1% BSA, 0,2% Triton in PBS for
15 minutes at RT and incubated with Anti-phospho-Histone
H2A.X Ser 139 primary antibody (Millipore) for 2 h at RT. After
4 washes of 5 minutes each, coverslips were incubated with an
Alexa-488 goat anti-mouse antibody (Life Technologies) for 1 h at
RT, counterstained with DAPI and mounted in Moviol on glass
slides. Samples were observed with an epifluorescent microscope
Leica DM IL LED FLUO (Leica Microsystems) and at least 300
cells were counted in triplicate experiments.
Western blotting
IMR90 cells were harvested following washing with PBS. Cells
were lysed in a buffer containing 0.02M HEPES (pH 7.9), 0.4M
NaCl, 0.1% NP-40, 10% (v/v) glycerol, 1 mM NaF, 1 mM
sodium orthovanadate and a protease inhibitory cocktail (Sigma
Chemical Co. St. Louis, MO). Extracts were subjected to Sodium
Dodecyl Sulfate (SDS)-polyacrylamide gel electrophoresis, fol-
lowed by blotting to PVDF. The blots were probed with antibodies
from Santa Cruz to human CDCA2, ID4, p53, p21, b-actin and
a-tubulin; from Cell Signaling to human phospho-ATM (Ser
1981) and phospho-p53 (Ser 15) ; from Sigma-Aldrich to human
ATM.
Statistical analysis
Statistical analysis were carried out using the Student’s t test and
data were considered significant at a value of p,0.05.
Results
A set of mRNAs is down-regulated in human senescent
fibroblasts
To select candidate targets of SAmiR-494 or SAmiR-486-5p,
we speculated that SAmiRs induced upon Replicative Senescence
(RS) of HDFs could contribute to the suppression of genes that
must be kept down-regulated on the induction of RS. Thus, we
generated a list of mRNAs down-regulated on HDFs senescence
by comparing the normalized data of six different microarray gene
expression profiles available on public databases [23–28]. This
analysis allowed to select 139 mRNAs down-regulated($1.5 folds)
in at least 3 out of 6 different arrays (Table S1). As summarized in
Fig. 1A, we analyzed the 139 mRNAs for the presence of
consensus motifs for SAmiR-494 and/or for SAmiR-486-5p, by
using four different target prediction algorithms (Target Scan v6.2,
miRDB, Diana, miRanda) and focusing on the results common to
at least two algorithms. This screening led to the generation of the
list of candidate targets shown in Fig. 1B, with 20 putative targets
of SAmiR-494, 7 of SAmiR-486-5p and 3 common to both
SAmiRs (in grey). Among them, there are many mRNAs encoding
proteins involved in cell cycle regulation (e.g. CCNE2, NUSAP1,
ZWINT) and DDR (e.g. RAD51, RAD51AP1, DEK), two
biological processes modified by ectopic expression of SAmiRs
[17] (see also Table S1 for functional annotations). Interestingly,
some of the candidates are members of the same protein family
(e.g. BUB3 and BUB1b; CDCA2, CDCA4 and CDCA7; RFC2
and RFC3). We excluded BIRC5 (survivin) from further
investigation, as it was already validated by others [31].
To validate the results of our comparative analysis, we
investigated in IMR90 cells the expression profile of putative
Novel SAmiR Direct Targets
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Figure 1. Strategy to identify putative targets of SAmiRs. A) The 3’UTR sequences of the 139 mRNAs down-regulated in replicative senescent
fibroblasts and reported in Table S1 were analyzed with four different target prediction algorithms. This in silico analysis revealed 30 putative SAmiR
targets: 20 of SAmiR-494, 7 of SAmiR-486-5p and 3 common to both SAmiRs. B) List of the 30 predicted target genes of both SAmiR-494 or SAmiR-
486-5p. In grey, the three putative targets common to both SAmiRs.
doi:10.1371/journal.pone.0098669.g001
Novel SAmiR Direct Targets
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targets upon induction of RS, EIS and DIS (Fig. 2). With the
exception of CDCA7, SOCS2 and ZNF367, whose expression in
IMR90 was undetectable (not shown), the results obtained by Real
Time PCR demonstrated a common signature of gene expression
in replicative and stress-induced senescence, with 17 out of 26
putative target genes that resulted significantly (p,0.05) down-
regulated, with a fold variation$2, upon RS, 14 out of 26 upon
EIS and 7 out of 26 upon DIS. These results prompted us to select
for further investigation the 7 candidates, highlighted in Fig. 2 by a
star, whose expression resulted down-regulated in all the examined
conditions (RS, EIS and DIS).
A subset of putative targets are down-regulated upon
SAmiR over-expression in human fibroblasts
In order to identify direct targets of SAmiRs, considering that
mRNAs targeted by a miR are generally degraded [32–33], we
analyzed by Real Time PCR the mRNA levels of BUB1b,
CDCA2, FOXM1, ID4, MKI67, NUSAP1 and PCOLCE at day
2 after the transfection of the cognate synthetic SAmiR precursor
(pre-miRs). As shown in Fig. 3A, CDCA2, FOXM1 and NUSAP1
resulted significantly (p,0.01) down-regulated 2 days after
SAmiR-494 pre-miR transfection, whereas, among SAmiR-486-
5p putative targets, ID4 and, at a lower extent, BUB1b, showed a
significant reduction upon pre-miR transfection.
CDCA2 and ID4 are direct target of SAmiR-494 and
SAmiR-486-5p, respectively
To address whether CDCA2, FOXM1, NUSAP1, ID4 and
BUB1b, whose mRNAs resulted reduced after SAmiR over-
expression, were direct targets, luciferase constructs containing
their 39 UTR sequences were generated. As shown in Fig. 3B, in
the case of CDCA2 and ID4 the reporter gene expression was
significantly reduced by SAmiR-494 or SAmiR-486-5p pre-miR
transfection, respectively, with a variation of relative luciferase
expression similar to the positive control OLFM4 (N). In contrast,
the co-transfection of FOXM1, NUSAP1 or BUB1b luciferase
constructs with the cognate SAmiR didn’t show any change in
luciferase expression compared to unrelated pre-miR transfected
cells (Fig. S3A).
To further characterize the functionality of predicted target sites
in the 3’UTRs of CDCA2 and ID4, the corresponding reverse
fragments or the fragments mutated at the seed region of putative
target sites were also generated. As shown in Fig. 3B, the luc-
reverse constructs (R), as well as the constructs bearing mutated
UTRs (M) were unaffected by the cognate SAmiR transfection (see
also Fig. 3C for point mutations into SAmiRs seed regions), thus
strongly suggesting that CDCA2 and ID4 were direct targets of
selected SAmiRs.
We also investigated the expression profiles of the two targets by
Western blot analysis, upon SAmiRs over-expression or down-
regulation in PDL 33 IMR90 cells. As shown in Fig. 3D and 3E,
the decrease in CDCA2 and ID4 endogenous expression levels
was well detectable at protein level. Noteworthy, the transfection
of miR inhibitors caused the increase of target expression levels.
All together, these data demonstrated that CDCA2 and ID4 are
direct targets of SAmiRs-494 and SAmiR-486-5p, respectively.
Knock-down of CDCA2 or ID4 in young human primary
fibroblasts does not induce senescence
To analyze the role of CDCA2 and ID4 in senescence, we asked
whether their knock-down by RNAi in young cells was able to
induce premature senescence, as the up-regulation of the cognate
SAmiRs does. To this aim, we transfected siRNAs designed to
silence CDCA2 or ID4 in young IMR90 at PDL 33 individually or
as a mixture (Fig. S3B), and then we analyzed the cells until ten
days after transfection, in order to detect any signs of senescence,
as the decreasing of cell proliferation by BrdU incorporation, the
change in cell morphology or the appearance of SA-b-gal. As
showed in Fig. 4A, the knock-down of these genes seemed to be
unable to affect cell proliferation, although a weak but significant
decrease in BrdU incorporation was detected in siCDCA2 cells.
Accordingly, knock-down cells did not senesce prematurely, as
demonstrated by the absence of SA-b-gal staining 10 days after
siRNA transfection (Fig. 4B). Probably, neither the transient
Figure 2. Expression profile of putative targets upon the induction of replicative or stress-induced senescence. The expression levels
of the 26 candidates were measured by Real Time PCR in replicative (RS: IMR90 cells at PDL 58), etoposide- (EIS: PDL 33 IMR90 cells treated with
20 mM etoposide for 24 h and then subcultivated for additional 10 days) and DEM-induced (DIS: PDL 33 IMR90 cells treated with 150 mM DEM on
alternate days for 10 days) senescent cells. The mRNA relative expression was calculated by assigning the arbitrary value 1 to the amount found in
young or DMSO-treated cells. SD is used to refer to the values obtained in 2 different experiments. Results showed that 7 mRNAs, highlighted by a
star, resulted significantly (p,0.05) down-regulated, with a cut-off$2 folds, in all conditions.
doi:10.1371/journal.pone.0098669.g002
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down-regulation of individual SAmiR target, nor the knock-down
of both targets have the ‘‘strength’’ to switching-on the senescence
program, as the contemporaneous reduction of many targets
exerted by SAmiR’s over-expression do.
Nevertheless, the down-regulation of CDCA2 or ID4 caused by
the up-regulation of cognate SAmiRs could contribute to the
acquisition of the final senescence phenotype. Thus, we investi-
gated the possible role of CDCA2 or ID4 in cellular senescence by
determining the effects of their over-expression.
Adoptive expression of CDCA2 promotes cell cycle
progression in EIS
We transfected CDCA2 or ID4 in young PDL 33 IMR90 cells,
one day before the induction of EIS or DIS. Then, we monitored
the progression of senescence by checking for BrdU incorporation,
cell morphology changes and appearance of SA-b-gal.
While DIS program seemed to be unaffected, the transient over-
expression of CDCA2, but not ID4, was able to counteract the EIS
program, promoting cell cycle progression (Fig. 5A), despite the
DNA damage induced by etoposide (Fig. S4A). However, this is a
Figure 3. Expression profile of putative targets upon SAmiRs ectopic expression and validation of CDCA2 and ID4. A) Expression
levels of SAmiR-494 and SAmiR-486-5p putative targets 2 days after the transfection of the cognate SAmiR pre-miR in PDL 33 IMR90 cells. mRNA
levels were measured by Real Time PCR and mRNA relative expression was calculated by assigning the arbitrary value 1 to the amount found in
control cells transfected with a scramble pre-miR. SD refers to the values obtained in 3 different experiments and the difference was significant (** p,
0.01; * p,0.05). The quantification of the expression levels of SAmiRs after their ectopic over-expression is reported in Panel A of Figure S2. B)
Luciferase constructs bearing the normal 3’UTRs (N), reverse 3’UTRs (R) or mutated 3’UTRs (M) of CDCA2 and ID4 were transfected in HEK293 cells
together with the cognate pre-miR or control pre-miR. The normal and reverse 3’UTR of OLFM4 were used as positive control. Luciferase levels were
reported as fold changes compared to the values measured in control pre-miR transfected cells, after normalization with Renilla luciferase activity. SD
refers to the values obtained in 3 different experiments (* p,0.01). C) Wild type seed regions of SAmiR-494 and SAmiR-486-5p, respectively present
into the 3’UTRs of CDCA2 and ID4, compared to the mutated seed regions used for luciferase assays. D) Western blot analysis of CDCA2 in IMR90 cells
over-expressing SAmiR-494 (pre-miR) or a specific SAmiR-494 inhibitor (anti-miR). E) Western blot analysis of ID4 in IMR90 cells over-expressing
SAmiR-486-5p (pre-miR) or a specific SAmiR-486-5p inhibitor (anti-miR). In both cases, the proteins resulted suppressed by the SAmiR over-
expression, as well as they resulted up-regulated by the anti-miR transfection, if compared to the control scramble transfected cells. The
quantification of the expression levels of SAmiRs after their ectopic over-expression in D and E is reported in Panel B of Figure S2.
doi:10.1371/journal.pone.0098669.g003
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temporary effect, as CDCA2 over-expressing cells finally arrested
their growth and showed SA-b-gal accumulation, just like control
cells (Fig. S4B).
Etoposide provokes DNA strand breaks that induce senescence
through the activation of the p53 pathway [13]. Furthermore, it
has been demonstrated that, in human non-tumorigenic cells
(MCF10A), the over-expression of CDCA2 attenuates DDR
activation induced by etoposide treatment by recruiting PP1c
phosphatase to chromatin at damaged sites and causing the
dephosphorylation of activated ATM [34]. This phenomenon
could also explain the resistance to EIS showed by IMR90 cells
over-expressing CDCA2. Therefore, we measured ATM activa-
tion in CDCA2 over-expressing cells 24 h after EIS induction.
Figure 4. Knock-down of CDCA2, ID4 or both does not induce premature senescence in PDL 33 IMR90 cells. A) siRNAs designed to
target the coding sequence of CDCA2 or ID4 were transfected, individually or as a mix, in PDL 33 IMR90 cells to knock-down the expression levels of
target genes. After 72 h, transfected cells were incubated with BrdU for 4 h, then coverslips were fixed, incubated with a primary anti-BrdU antibody,
washed and incubated with a secondary fluorescein-conjugated antibody, counterstained with Hoechst-33258 and counted by immunofluorescence.
Counts of at least 1,000 cells were averaged and expressed as fold changes6SD, with respect to scrambled transfected cells (*** p,0.001). B) siRNA
transfected cells were subcultivated for 10 days and stained for SA-b-gal. Counts of at least 300 cells were averaged and expressed as fold
changes6SD, with respect to scrambled transfected cells.
doi:10.1371/journal.pone.0098669.g004
Figure 5. Adoptive expression of CDCA2 promotes cell cycle progression in Etoposide-Induced Senescence. A) CDCA2 and ID4 coding
sequences were transfected in PDL 33 IMR90 cells. Cells transfected with CMV-NEO plasmid were used as control. After 24 h, transfected cells were
treated with 20 mM etoposide or 150 mM DEM for 24 h and then incubated with BrdU for 4 h. Coverslips were then fixed, incubated with primary
anti-BrdU and secondary fluorescein-conjugated antibodies, counterstained with Hoechst-33258 and counted by immunofluorescence. Counts of at
least 800 cells were averaged and expressed as fold changes6SD, with respect to control transfected cells (***p,0.01). B) and C) PDL 33 IMR90 cells
were transfected with the coding sequence of CDCA2. After 24 h, transfected cells were treated with 20 mM etoposide for 24 h and then were
collected to obtain protein extracts. Cell extracts from CMV-neo over-expressing cells served as control. Western Blot analysis was used to detect the
levels of phosphorylated ATM (p-ATM Ser1981), ATM, phosphorylated p53 (p-p53 Ser15), p53, p21Cip1 and CDCA2 in the cell lysates. b-actin was used
as a loading control.
doi:10.1371/journal.pone.0098669.g005
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As shown in Fig. 5B and 5C, the over-expression of CDCA2 is
accompanied by a reduction of ATM activation. This results in a
reduced activation of p53 and a consequent weak expression of the
cyclin-dependent kinase inhibitor p21Cip1, which can explain the
sustained cell proliferation observed despite etoposide treatment.
All these data demonstrate that also in primary human cells
CDCA2 over-expression is able to antagonize the activation of
ATM-dependent signal transduction modulating DDR sensitivity,
thus preventing the arrest of cell-cycle progression of premature
senescence via decreased expression of CDKIs.
Discussion
In this study, with the intent to find novel direct targets of two
specific SAmiRs previously associated to the induction and
maintenance of cellular senescence [17], we took advantage of
gene expression data available in literature to select by a
comparative analysis and validate a subset of genes, whose
expression was strongly reduced in replicative and stress-induced
senescent cells. Among these genes we found that CDCA2, a
specific nuclear regulatory subunit of protein phosphatase 1 c
(PP1c), and ID4, a member of a family of helix-loop-helix
transcription factors, are direct targets of SAmiR-494 and SAmiR-
486-5p, respectively.
In our study, the down-regulation in HDFs of CDCA2, ID4 or
both fails to cause a massive cell cycle arrest typical of premature
senescence, that instead occurs after the over-expression of their
negative regulators, SAmiR-494 or SAmiR-486-5p. Nevertheless,
the ectopic expression of CDCA2, but not of ID4, was able to
partially counteract the progression of EIS by the reduction of
ATM activation, thus avoiding the cell cycle arrest caused by the
activation of p53 and of DNA damage checkpoints after etoposide
treatment. This would make cells less sensitive to DNA damage.
Thus, it can be speculated that the down-regulation of CDCA2
expression that occurs in HDFs during cellular senescence could
contribute to the accumulation of DNA damage that, in turn,
sustains, rather than provokes, the senescence program.
CDCA2, also known as Repo-Man, is involved in cell cycle
regulation [35–38), as well as in PP1c-dependent essential DDR
regulation [34]. Our data are in accordance with previous findings
from Peng and colleagues, reporting that CDCA2 recruits PP1c to
chromatin to antagonize activation of ATM-dependent signal
transduction in pre-malignant (not cancerous) cells [34].
Moreover, CDCA2-dependent DDR regulation is strengthened
by CDCA2 over-expression during cancer progression, resulting in
reduced DDR sensitivity. CDCA2 is frequently over-expressed in
many tumor cells, as neuroblastoma, melanoma, breast cancer and
in oral squamous cell carcinoma [39]. In particular, experiments
on oral cancer cell lines showed that suppression of CDCA2
expression with shRNA significantly inhibits cellular proliferation,
by arresting cell-cycle progression at the G1 phase through
activation of the DDR in vitro, thus suggesting that up-regulation of
CDCA2 in tumor cells might prevent the arrest of cell-cycle
progression, via decreased expression of CDKIs and regulation of
the DDR.
However, in our study CDCA2 over-expressing cells finally
encounter a senescent growth arrest. This behavior might be
explained by the fact that the reduction of p53 and p21 activation
is only partial. Other mechanisms, parallel to ATM activation,
may be involved in supporting the phosphorylation of p53.
Concerning ID4, it is an helix-loop-helix transcription factor
that, having lost the basic DNA-binding domain, acts as
dominant-negative regulator by forming inactive heterodimeric
complexes with other helix-loop-helix transcription factors [40]. It
performs different regulatory functions mainly during embryo-
genesis, being involved in the neural stem cell, oligodendrocyte
and astrocyte differentiation.
Like CDCA2, ID4 is expressed in several tumors where it seems
to play a key role in cellular transformation, immortalization,
invasion, and in the metastatic process [41–42]. Thus, a decrease
in ID4 expression levels could be one of the mechanisms adopted
by cellular senescence to antagonize the tumor development in
pre-cancerous cells. Nevertheless, the expression of ID4 is
epigenetically silenced in prostate cancer and, very recently, it
has been demonstrated that ectopic over-expression of ID4
promotes cellular senescence in prostate cancer cell line DU145
by increasing the expression of p16, p21, p27, E-cadherin and
vimentin, but down-regulating E2F1 expression. ID4 also poten-
tiated the effect of doxorubicin induced senescence and apoptosis
[43]. These findings suggest that the role of ID4 in cellular
senescence could be strictly dependent on tissue or cell types.
In conclusion, we have identified CDCA2 and ID4 as new
direct targets of two different miRs, whose up-regulation in HDFs
is correlated to the induction of cellular senescence. As expected,
both targets are down-regulated during replicative- or stress-
induced senescence, but cannot induce senescence when silenced
in young HDFs. Nevertheless, for CDCA2, our results are in
accordance with previous findings in pre-malignant (not cancer-
ous) or tumor cells, in which the levels of CDCA2 determine the
activation threshold of the DNA damage checkpoint. Thus, our
results indicate that CDCA2 sets the threshold for checkpoint
activation also in HDFs.
Supporting Information
Figure S1 Characterization of senescent IMR90 cells. A)
Characterization of replicative senescent IMR90 cells. Primary
human fibroblasts IMR90 were grown in DMEM supplemented
with 10% (v/v) fetal bovine serum and 1% penicillin/streptomycin
for some months, until PDL 58. B) Characterization of cellular
senescence induced by etoposide treatment. PDL 33 IMR90 cells
were exposed to etoposide 20 mM for 24 h and then cultured for
10 days before harvesting. C) Characterization of cellular
senescence induced by DEM treatment. PDL 33 IMR90 cells
were chronically exposed to DEM 150 mM on alternate days for
10 days before harvesting. In all cases, cellular senescence was
assessed by SA-b-gal staining and gene expression profile [4]. For
SA-b-gal staining, representative images of control and senescent
cells are reported. For each experiment, at least 300 cells were
counted. For gene expression profiling, quantitative Real-Time
PCR analysis of cyclin A (CyclA), thymidylate synthase (THY),
cyclin-selective ubiquitin carrier protein (UBI), interleukin-6 (IL6),
cyclin-dependent kinase inhibitors p21Cip1 (p21) and p16INK4A
(p16) mRNAs are showed. Results are the mean of triplicate
determinations.
(TIFF)
Figure S2 Quantification of SAmiR expression levels
after their ectopic over-expression. The expression levels of
SAmiR-494 and SAmiR-486-5p were measured by Real Time
PCR in PDL 33 IMR90 cells transfected with 100 nM pre-miR.
The microRNA relative expression was calculated by assigning the
arbitrary value 1 to the amount found in control pre-miR
transfected cells. SD is used to refer to the values obtained in 3
different experiments. In all cases, the difference was significant (p
, 0.01). A) Data refers to SAmiR’s over-expression of Figure 3A;
B) data refers to SAmiR’s over-expression of Figure 3D and 3E.
(TIFF)
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Figure S3 A) Luciferase assay of unvalidated SAmiR
predicted target genes. Luciferase constructs bearing the
normal 3’UTRs of FOXM1, NUSAP1 (predicted targets of
SAmiR-494) and BUB1b (predicted target of SAmiR-486-5p) were
transfected in HEK293 cells, together with the specific SAmiR
pre-miR, control pre-miR or an unrelated pre-miR. Luciferase
levels were reported as fold changes compared to the values
measured in control pre-miR transfected cells, after normalization
with Renilla luciferase activity. B) SAmiR’s target knock-
down by siRNAs. The expression levels of CDCA2 and ID4
were measured by Real Time PCR in PDL 33 IMR90 cells
transfected with 100 nM siRNAs, individually or as a mix. The
mRNA relative expression was calculated by assigning the
arbitrary value 1 to the amount found in scramble-transfected
cells. SD is used to refer to the values obtained in 3 different
experiments. In all cases, the difference was significant (p , 0.05).
(TIFF)
Figure S4 A) Etoposide treatment of IMR90 cells over-
expressing CDCA2 induces cH2AX foci. PDL 33 IMR90
cells were transfected with control CMV-NEO vector or with
CMV-CDCA2. After 24 h, transfected cells were treated with
20 mM etoposide. Cells were fixed and examined by immunoflu-
orescence for a-H2AX phosphorylated on Ser139 (cH2AX) at 0, 6
or 18 hours after treatment. Coverslips were washed and
incubated with Alexa-488 Goat anti-rabbit antibody and coun-
terstained with DAPI. Counts of at least 300 cells were averaged
and expressed as percent of cells positive to the presence of
cH2AX foci 6 SD. B) Etoposide treatment of IMR90 cells
over-expressing CDCA2 induces premature senescence.
PDL33 IMR90 cells were transfected with control vector or a
vector containing the coding sequence of human CDCA2 gene.
After 24 h, transfected cells were treated with 20 mM etoposide for
24 h and then were subcultivated for 10 days before harvesting.
Cellular senescence was assessed by SA-b-gal staining. At least 300
cells were counted. Representative images of control and senescent
cells are showed.
(TIFF)
Table S1 Genes whose expression is down-regulated
during senescence of human diploid fibroblasts.
(PDF)
Table S2 Primer pairs for Real Time PCR.
(PDF)
Table S3 Primer pairs for plasmid construction.
(PDF)
Acknowledgments
We thank Prof. Tommaso Russo for critical reading of the manuscript and
for helpful discussions.
Author Contributions
Conceived and designed the experiments: MN FP FC. Performed the
experiments: MN MC MS EL FP. Analyzed the data: MN FP LP RF FC.
Wrote the paper: FP FC.
References
1. Hayflick L, Moorhead PS (1961) The serial cultivation of human diploid cell
strains. Exp Cell Res 25: 585–621.
2. Miura T, Mattson MP, Rao MS (2004) Cellular lifespan and senescence
signaling in embryonic stem cells. Aging Cell 3: 333–343.
3. Campisi J, d’Adda di Fagagna F (2007) Cellular senescence: when bad things
happen to good cells. Nat Rev Mol Cell Biol 8: 729–740.
4. Rodier F, Campisi J (2011) Four faces of cellular senescence. J Cell Biol 192 (4):
547–556.
5. Mun˜os-Espı´n D, Can˜amero M, Maraver A, Go´mez-Lo´pez G, Contreras J, et al.
(2013) Programmed cell senescence during mammalian embryonic develop-
ment. Cell 155 (5): 1104–1118.
6. Storer M, Mas A, Robert-Moreno A, Pecoraro M, Ortells MC, et al. (2013)
Senescence is a developmental mechanism that contributes to embryonic growth
and patterning. Cell 155 (5): 1119–1130.
7. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, et al. (1998) Extension
of life-span by introduction of telomerase into normal human cells. Science 279:
349–352.
8. Rodier F, Coppe JP, Patil CK, Hoeijmakers WAM, Munoz DP, et al. (2009)
Persistent DNA damage signaling triggers senescence-associated inflammatory
cytokine secretion. Nat Cell Biol 11: 973–979.
9. d’Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, et al.
(2003) A DNA damage checkpoint response in telomere-initiated senescence.
Nature 426: 194–198.
10. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras
provokes premature cell senescence associated with accumulation of p53 and
p16INK4a. Cell 88: 593–602.
11. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, et al. (1998) Premature
senescence involving p53 and p16 is activated in response to constitutive MEK/
MAPK mitogenic signaling. Genes Dev 12: 3008–3019.
12. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, et al. (2006)
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by
DNA damage checkpoints. Nature 444: 633–637.
13. Poele Te RH, Okorokov AL, Jardine L, Cunnings J, Joel SP (2002) DNA
damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer
Res 62: 1876–83.
14. Faraonio R, Pane F, Intrieri M, Russo T, Cimino F (2002) In vitro acquired
cellular senescence and aging-specific phenotype can be distinguished on the
basis of specific mRNA expression. Cell Death Differ 9: 862–864.
15. Parrinello S, Samper E, Krtolica A, Goldstein J, Melov S, et al. (2003) Oxygen
sensitivity severely limits the replicative lifespan of murine fibroblasts. Nat Cell
Biol 5: 741–747.
16. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell
136: 215–33.
17. Faraonio R, Salerno P, Passaro F, Sedia C, Iaccio A, et al. (2012) A set of
miRNAs participates in the cellular senescence program in human diploid
fibroblasts. Cell Death Differ 19 (4): 713–721.
18. Gorospe M, Abdelmohsen K (2011) MicroRegulators come of age in senescence.
Trends Genet 27: 233–41.
19. Mancini M, Saintigny G, Mahe´ C, Annicchiarico-Petruzzelli M, Melino G, et al.
(2012) MicroRNA-152 and -181a participate in human dermal fibroblasts
senescence acting on cell adhesion and remodeling of the extra-cellular matrix.
Aging (Albany) 4: 843–53.
20. Smith-Vikos T, Slack FJ (2012) MicroRNAs and their roles in aging. J Cell Sci
125: 7–17.
21. Kim YJ, Hwang SH, Lee SY, Shin KK, Cho HH, et al. (2012) miR-486-5p
induces replicative senescence of human adipose tissue-derived mesenchymal
stem cells and its expression is controlled by high glucose. Stem Cells Dev 21:
1749–1760.
22. Ohdaira H, Sekiguchi M, Miyata K, Yoshida K (2012) MicroRNA-494
suppresses cell proliferation and induces senescence in A549 lung cancer cells.
Cell Prolif 45 (1): 32–38.
23. Binet R, Ythier D, Robles AI, Collado M, Larrieu D, et al. (2009) WNT16B is a
new marker of cellular senescence that regulates p53 activity and the
phosphoinositide 3-kinase/AKT pathway. Cancer Res 69 (24): 9183–91.
24. Zhang H, Pan KH, Cohen SN (2003) Senescence-specific gene expression
fingerprints reveal cell-type-dependent physical clustering of up-regulated
chromosomal loci. Proc Natl Acad Sci U S A 100 (6): 3251–6.
25. Hardy K, Mansfield L, Mackay A, Benvenuti S, Ismail S, et al. (2005)
Transcriptional networks and cellular senescence in human mammary
fibroblasts. Mol Biol Cell 16 (2): 943–53.
26. Zhang H, Herbert BS, Pan KH, Shay JW, Cohen SN (2004) Disparate effects of
telomere attrition on gene expression during replicative senescence of human
mammary epithelial cells cultured under different conditions. Oncogene 23 (37):
6193–8.
27. Schwarze SR, DePrimo SE, Grabert LM, Fu VX, Brooks JD, et al. (2002) Novel
pathways associated with bypassing cellular senescence in human prostate
epithelial cells. J Biol Chem 277 (17): 14877–83.
28. Johung K, Goodwin EC, Di Maio D (2007) Human papillomavirus E7
repression in cervical carcinoma cells initiates transcriptional cascade driven by
the retinoblastoma family, resulting in senescence. J Virol 81 (5): 2102–16.
29. Oh HK, Tan AL-K, Das K, Ooi CH, Deng NT, et al. (2011) Genomic loss of
miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in
gastric cancer. Clin Cancer Res 17: 2657–2667.
30. Dimri GP, Lee X, Basile G, Acosta M, Scott G, et al. (1995) A biomarker that
identifies senescent human cells in culture and in aging skin in vivo. Proc Natl
Acad Sci U S A 92: 9363–9367.
Novel SAmiR Direct Targets
PLOS ONE | www.plosone.org 9 June 2014 | Volume 9 | Issue 6 | e98669
31. Diakos C, Zhong S, Xiao Y, Zhou M, Vasconcelos GM, et al. (2010) TEL-
AML1 regulation of survivin and apoptosis via miRNA-494 and miRNA-320a.
Blood 116 (23): 4885–93.
32. Visvanathan J, Lee S, Lee B, Lee JW, Lee SK (2007) The microRNA miR-124
antagonizes the anti-neural REST/SCP1 pathway during embryonic CNS
development. Genes Dev 21: 744–749.
33. Ziegelbauer JM, Sullivan CS, Ganem D (2009) Tandem array-based expression
screens identify host mRNA targets of virus-encoded microRNAs. Nat Genet 41:
130–134.
34. Peng A, Lewellyn AL, Schiemann WP, Maller JL (2010) Repo-Man controls a
protein phosphatase 1-dependent threshold for DNA damage checkpoint
activation. Curr Biol 20 (5): 387–396.
35. Trinkle-Mulcahy L, Andersen J, Lam YW, Moorhead G, Mann M, et al. (2006)
Repo-Man recruits PP1 gamma to chromatin and is essential for cell viability.
J Cell Biol 172: 679–692.
36. Vagnarelli P, Hudson DF, Ribeiro SA, Trinkle-Mulcahy L, Spence JM, et al.
(2006) Condensin and Repo-Man-PP1 co-operate in the regulation of
chromosome architecture during mitosis. Nat Cell Biol 8: 1133–1142.
37. Qian J, Lesage B, Beullens M, Van Eynde A, Bollen M (2011) PP1/Repo-man
dephosphorylates mitotic histone H3 at T3 and regulates chromosomal aurora B
targeting. Curr Biol 21: 766–773.
38. Vagnarelli P, Ribeiro S, Sennels L, Sanchez-Pulido L, de Lima Alves F, et al.
(2011) Repo-Man Coordinates Chromosomal Reorganization with Nuclear
Envelope Reassembly during Mitotic Exit. Dev Cell 21: 328–342.
39. Uchida F, Uzawa K, Kasamatsu A, Takatori H, Sakamoto Y, et al. (2013)
Overexpression of CDCA2 in Human Squamous Cell Carcinoma: Correlation
with Prevention of G1 Phase Arrest and Apoptosis. PLoS ONE 8 (2): e56381.
40. Massari ME, Murre C (2000) Helix-loop-helix proteins: regulators of
transcription in eucaryotic organisms. Mol Cell Biol 20: 429–440.
41. Ruzinova MB, Benezra R (2003) Id proteins in development, cell cycle and
cancer. Trends Cell Biol 13: 410–418.
42. Iavarone A, Lasorella A (2006) ID proteins as targets in cancer and tools in
neurobiology. Trends Mol Med 12: 588–594.
43. Carey JP, Knowell AE, Chinaranagari S, Chaudhary J (2013) ID4 promotes
senescence and sensitivity to doxorubicin-induced apoptosis in DU145 prostate
cancer cells. Anticancer Res 33 (10): 4271–8.
Novel SAmiR Direct Targets
PLOS ONE | www.plosone.org 10 June 2014 | Volume 9 | Issue 6 | e98669
